Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidimod dispersible tablets as adjunctive therapy for recurrent urinary tract infection
ChiCTR2000032512Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Apr 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pidotimod in urinary tract infection (UTI) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Number of recurrent urinary tract infections within 6 months after end of medication. Started Apr 2020; status: recruiting.
02
Drugs
pidotimod
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on ChiCTR2000032512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032512.